Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Market context The GLP-1 market continues to expand rapidly, driven by: - rising global prevalence of type 2 diabetes - obesity rates that have tripled since the 1960s - increasing demand for effective, scalable chronic disease therapies With more than $650B in branded biologics expected to lose patent protection over the next decade, generics and biosimilars are positioned for significant growth
Overweight and obese patients should gain between 15-25 lb (6.8-11.3 kg) and 11-20 lb (5.0-9.1 kg) respectively
Whilst emerging research explores links between metabolic health and endometriosis, Mounjaro is not approved by the MHRA or EMA for this condition
It is also a weekly injection
Explore clinical trial opportunities
US$ 27.20
US$ 21.11
US$ 24.95
US$ 25.68
